These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 12497176

  • 1. Plasma steroid hormones, surgery for benign prostatic hyperplasia, and severe lower urinary tract symptoms.
    Platz EA, Kawachi I, Rimm EB, Longcope C, Stampfer MJ, Willett WC, Giovannucci E.
    Prostate Cancer Prostatic Dis; 1999 Dec; 2(5/6):285-289. PubMed ID: 12497176
    [Abstract] [Full Text] [Related]

  • 2. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III).
    Rohrmann S, Nelson WG, Rifai N, Kanarek N, Basaria S, Tsilidis KK, Smit E, Giovannucci E, Platz EA.
    Urology; 2007 Apr; 69(4):708-13. PubMed ID: 17445656
    [Abstract] [Full Text] [Related]

  • 3. Race, ethnicity and benign prostatic hyperplasia in the health professionals follow-up study.
    Platz EA, Kawachi I, Rimm EB, Willett WC, Giovannucci E.
    J Urol; 2000 Feb; 163(2):490-5. PubMed ID: 10647663
    [Abstract] [Full Text] [Related]

  • 4. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men.
    Trifiro MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C, Barrett-Connor E.
    BJU Int; 2010 Jun; 105(11):1554-9. PubMed ID: 20002438
    [Abstract] [Full Text] [Related]

  • 5. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JL.
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [Abstract] [Full Text] [Related]

  • 6. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M, Lukacs B, Matzkin H, Alcaraz A, Elhilali M, Vallancien G.
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [Abstract] [Full Text] [Related]

  • 7. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK, Garcia L, Patron N, Moh LC, Sundram M, Leungwattanakij S, Pripatnanont C, Cheng C, Chi-Wai M, Loi-Cheong N.
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [Abstract] [Full Text] [Related]

  • 8. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
    Emberton M, Elhilali M, Matzkin H, Harving N, van Moorselaar J, Hartung R, Alcaraz A, Vallancien G, Alf-One Study Group.
    Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
    [Abstract] [Full Text] [Related]

  • 9. Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia.
    Roberts RO, Bergstralh EJ, Farmer SA, Jacobson DJ, Hebbring SJ, Cunningham JM, Thibodeau SN, Lieber MM, Jacobsen SJ.
    Prostate; 2006 Mar 01; 66(4):392-404. PubMed ID: 16302261
    [Abstract] [Full Text] [Related]

  • 10. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey.
    Litman HJ, Bhasin S, O'Leary MP, Link CL, McKinlay JB, BACH Survey Investigators.
    BJU Int; 2007 Aug 01; 100(2):321-6. PubMed ID: 17506868
    [Abstract] [Full Text] [Related]

  • 11. Sexually transmitted infections, prostatitis, ejaculation frequency, and the odds of lower urinary tract symptoms.
    Sutcliffe S, Giovannucci E, De Marzo AM, Willett WC, Platz EA.
    Am J Epidemiol; 2005 Nov 01; 162(9):898-906. PubMed ID: 16177142
    [Abstract] [Full Text] [Related]

  • 12. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M, Rosenberg MT, Perelman MA.
    Clin Ther; 2006 Jan 01; 28(1):13-25. PubMed ID: 16490576
    [Abstract] [Full Text] [Related]

  • 13. The natural history of benign prostatic hyperplasia.
    Fitzpatrick JM.
    BJU Int; 2006 Apr 01; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
    [Abstract] [Full Text] [Related]

  • 14. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
    Paick SH, Meehan A, Lee M, Penson DF, Wessells H.
    J Urol; 2005 Mar 01; 173(3):903-7. PubMed ID: 15711315
    [Abstract] [Full Text] [Related]

  • 15. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
    Trachtenberg J.
    BJU Int; 2005 Jun 01; 95 Suppl 4():6-11. PubMed ID: 15871730
    [Abstract] [Full Text] [Related]

  • 16. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial.
    Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R, Barnett MJ, Goodman GE.
    Cancer Epidemiol Biomarkers Prev; 2003 Dec 01; 12(12):1410-6. PubMed ID: 14693730
    [Abstract] [Full Text] [Related]

  • 17. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M, Zinner N, Michel MC, Gittelman M, Chung MK, Madersbacher S.
    BJU Int; 2007 Aug 01; 100(2):249-53. PubMed ID: 17617135
    [Abstract] [Full Text] [Related]

  • 18. Circulating steroid hormones and the risk of prostate cancer.
    Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P, Giles GG.
    Cancer Epidemiol Biomarkers Prev; 2006 Jan 01; 15(1):86-91. PubMed ID: 16434592
    [Abstract] [Full Text] [Related]

  • 19. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG.
    BJU Int; 2006 Apr 01; 97(4):734-41. PubMed ID: 16536764
    [Abstract] [Full Text] [Related]

  • 20. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems.
    Parsons JK.
    J Urol; 2007 Aug 01; 178(2):395-401. PubMed ID: 17561143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.